Interleukin-17D Antibodies

Interleukin-17D (IL17D)

Induces expression of IL6, CXCL8/IL8, and CSF2/GM-CSF from endothelial cells.

.

Gene Information

Human
Gene Name:	IL17D
Uniprot:	Q8TAD2
Entrez:	53342

Family

Belongs to:
IL-17 family

Alternative Names

FLJ30846; IL17D; IL-17D; IL-17Dinterleukin 27; IL-22; IL-27interleukin-17D; IL27interleukin-27; interleukin 17D; Interleukin-27

Molecular Weight

Mass (kDA):
21.893 kDA

Genomic Context

Human
Location:	13q12.11
Sequence:	13; NC_000013.11 (20701105..20723100)

Tissue Specificity

Expressed preferentially in adipose, skeletal muscle and CNS.

Subcellular Localizations

Secreted.

Diseases

• Inflammation
• Gastrointestinal Diseases
• Acquired Immunodeficiency Syndrome
• Arthritis
• Simian Acquired Immunodeficiency Syndrome
• Coccidiosis
• Dental Caries
• Rheumatoid Arthritis
• Immune System Diseases

• Aspergillosis
• Typhoid Fever
• Infection By Aspergillus Fumigatus

Pathways

• Immune Response
• Pathogenesis
• Cell Activation
• Cytokine Production
• Cell Differentiation
• Oxidative Phosphorylation
• B Cell Differentiation
• B Cell Activation

• Viral Replication
• Hemopoiesis

PTMs

• Phosphorylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/IL17D

Best Uses Of The IL17D Marker

Interleukin-17D also known as IL17D, is a critical biological cytokine that animals have. Boster Bio produces antibodies which recognize IL17D. These antibodies can be monoclonal or polyclonal and react to IL-17D in a variety of animal samples. Boster Bio has developed antibodies against IL-17D by using rabbit and mouse. This cytokine stimulates cytokine formation and inhibits hemopoiesis.

IL17D marker

The IL17D genes is a marker of inflammation. The IL17D gene is an important marker of inflammation. This pathway links inflammation to oxidative damage via the Nrf2/IL-17D pathways. The nrf2 enzyme is encoded by the IL17D gene. ELISA tests can detect IL17D, which is found in many tissues, such as the liver and spleen.

It is found within various types of cancer cells. The IL17D protein is expressed in both animal and human models. In response to tBHQ treatment, human melanoma cell cells produce IL17D. This gene can be expressed either as a molecule or as a protein. IL17D gene expression is increased in response to treatment with H2O2.

The regulation the IL-17D genome is not only controlled through the IL17D genetic gene. In mice models, activation is crucial for inducing IL-17D. It is a therapeutic benefit in inflammatory diseases. It is important to identify other transcription factor that regulate the IL-17D genes. The IL17D gene expression markers may have therapeutic effect.

IL-17D is also a potent inhibitor of DC activation. It suppresses DC stimulation in Rag1/ mice. This suppression was a major mechanism of immune system function. In the experiment, DCs were exposed to LM-OVA-infected bacterial cultures and were sacrificed seven-days later. FACS staining was used to determine the cellularity and burden of bacteria in the spleen. DC activation marks such as IFNg were stained to determine their activity with IL-17D/ mice.

The IL-17D gene is derived from non-hematopoietic cells. It is suppressed in infection and inhibits activity of CD8-T cells. Infection-induced inflammation is a major reason for IL-17D-inflamed cells. Consequently, IL-17D-deficient mice do not respond to the infection. This does not mean that IL-17D doesn't play a critical role in this disease. However, a lack of IL-17D could hinder the immune system from fighting the infection.

17D live attenuated yellow flu vaccine

The Boster Bio Live attenuated yellow fever vaccine (17D) elicits robust and sustained immunity in humans. The vaccine's malaria epitope, which is located between NS2B-NS3, triggers a primary CD8+ T cells response. Although the 17D vaccine has been widely used as a universal vaccine, it can also be used to induce immunological induction or attenuation processes. While a single vaccine won't provide global protection, research suggests that a single vaccine can protect against several strains of YF.

Both 17DD as well as 17D strains carry the yellow fever virus, and both have similar adverse effects. Although 17DD is the most effective, the two strains have different immunogenicity and reactogenicities. Brazil conducted a study that found that the vaccine virus was transmitted through breast milk to infants. This is consistent in data from multiple labs. This evidence indicates that the vaccine is safe, effective, and protects infants.

Because of its high yields and low cost, the 17D virus, which is live attenuated, is one of the most promising vaccines for humans, it is also considered one among the most promising. The YF17D virus was subsequently genetically modified to express other flavivirus prM proteins. Recombinant, plasmid DNAs have the ability to deliver additional antigens for unrelated pathogens.

The recombinant 17D-Py virus has similar plateau titers, and exhibited faster growth kinetics compared to the 17D-Py parent strain. The virus-containing supernatants were used after transfection to infect naive SW-13 cell at low MOI. The supernatant was then analyzed for CTL epitopes. RTPCR was also used to determine CTL epitopes within the recombinantvirus.

Boster Bio Live 17D attenuated yellow fever vaccine contains an epitope from the malaria parasite embedded in its envelope protein. This epitope is distinctive and mimics 17D vaccine's immune response in humans. These results are promising. However, the study's design is still uncertain. The vaccine is still under development and is available for human use.

A new study has shown that the protective immune response to the Boster Bio Live attenuated Yellow-Fever vaccine 17D is durable. For 24 weeks, the recombinant 17D–Py injection was given to mice. Once that time had passed, the mice were subjected to 20,000 sporozoites for 1 week. The liver was able to inhibit parasite burden by a maximum of 4-8 weeks after immunization, and this effect remained significant for 24 weeks. Additionally, EEF development was inhibited by 99.9% by boosted sporozoites, and mice were protected from the recombinant.

As a pivotal instrument of public health, the YF-17D vaccine is important for worldwide health. However, the mechanisms that govern the vaccine's attenuation are poorly understood. However, Beck et al. Beck et.al. (2012) looked at the quasispecies diversity found in the Boster Bio Live attenuated yellow flu vaccine strain derived primarily from wild-type Asibi viruses. These studies have shown that the YF-17D vaccine has high mutation rates for viral RNA polymerases.

Anti-interleukin-17D antibodies

Interleukin-17D (IL-17D) is an inflammatory cytokine produced by the unique lineage of CD4 T cells. It has been shown to increase nitric oxygen production and promote IL6 expression. It has been shown to be associated with multiple autoimmune conditions, such as multiple-sclerosis and psoriasis. Boster Bio has tested their Interleukin-17D antibody using mouse and rabbit samples.

The study found that the neutralizing antibody titres ranged from 1:160 up to 1:20,000.480 in animals and humans. In animal experiments, neutralizing antibody titres were the dominant protective immune response under a variety of conditions including genetically-induced immune deficiencies. Humans are not affected by this. There are other factors that may influence why neutralizing antibodies may not provide sufficient protection against a particular disease.

The Boster Bio Anti IL17D IL17D antibody reacts positively with Human. It is available as monoclonal and multiclonal. It can also be stored at -20°C for up to a year and at 4°C for up to one month. The boster Bio Anti-IL17D antibody has undergone extensive validation using positive and negative samples. This ensures high specificity and affinity for all scientists.

These polyclonal antibody bind YF-17D molecule as well as its receptors. Antibody neutralizing antibody response to YF-17D is dependent on the function of the TNFRSF17 receptor. YF-17D is a cytokine induced in DCs that have a mixed Th2/Th2-type profile. Mice lacking MyD88 have a lower percentage of antigen-specific CD4+ T and CD8+ T lymphocytes.